Korean J Urol.  2007 Jul;48(7):696-700. 10.4111/kju.2007.48.7.696.

The Meaning of Metabolic Syndrome X in Patients Suffering with Benign Prostatic Hyperplasia

• Park JS
• Park JK

• KMID: 1990220
• DOI: http://doi.org/10.4111/kju.2007.48.7.696

Abstract

PURPOSE: We wanted to evaluate if metabolic syndrome X affects voiding symptoms and erectile function in those patients suffering with benign prostatic hyperplasia(BPH).
MATERIALS AND METHODS
Between January 2003 and May 2006, we analyzed 68 patients suffering with both BPH and metabolic syndrome X and 112 patients suffering with BPH, but not metabolic syndrome as controls. The diagnosis of metabolic syndrome was made according to the recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. The blood pressure, obesity, maximal flow rate, residual volume, International Prostate Symptom Score(IPSS), and the International Index of Erectile Function(IIEF) were all measured. The biochemical analyses included determining the levels of serum glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C) and prostate-specific antigen (PSA). The total prostate volume and transitional zone volume were measured via transrectal ultrasound. Statistical analysis was performed by using Student's t-test.
RESULTS
There were statistical differences between the two groups with respect to total cholesterol(p=0.045), triglycerides(p<0.001), HDL-C(p<0.001), glucose(p<0.001), blood pressure(p<0.001) and obesity(p<0.001), respectively. However, there was no significant difference on comparison of the total prostate volume and transitional zone volume, the maximal flow rate, the residual volume, IPSS, IIEF, PSA and LDL-C.
CONCLUSIONS
The results of this study suggest that BPH patients with metabolic syndrome X have higher total cholesterol, triglycerides, glucose, blood pressure and obesity, and lower HDL-C. Yet there was no significant difference in the voiding symptoms and erectile function between the patients with BPH who had or didn't have metabolic syndrome X.

Keyword

Benign prostatic hyperplasia; Metabolic syndrome X; Erectile dysfunction

MeSH Terms

Adult
Blood Glucose
Blood Pressure
Cholesterol
Consensus
Diagnosis
Education
Erectile Dysfunction
Humans
Lipoproteins
Male
Metabolic Syndrome X*
Obesity
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia*
Residual Volume
Triglycerides
Ultrasonography
Blood Glucose
Cholesterol
Lipoproteins
Prostate-Specific Antigen
Triglycerides

Reference

1. Kim JH, Shim BS, Hong YS. The relating factors of metabolic syndrome to benign prostatic hyperplasia. Korean J Urol. 2005. 46:1046–1050.

2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984. 132:474–479.

3. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am. 1995. 22:237–246.

4. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002. 106:599–604.

5. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999. 53:1–6.

6. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999. 8:29–36.

7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988. 37:1595–1607.

8. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori. 2004. 52:291–294.

9. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptom and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep. 2001. 2:297–301.

10. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology. 1995. 46(3):Suppl A. 23–25.

11. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses. 2001. 56:702–708.

12. Guay AT. Sexual dysfunction in the diabetic patient. Int J Impot Res. 2001. 13:Suppl 5. S47–S50.

13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002. 287:356–359.

14. Guirao Sanchez L, Garcia-Giralda Ruiz L, Sandoval Martinez C, Mocciaro Loveccio A. Erectile dysfunction in primary care as possible marker of health status: associated factors and response to sildenafil. Aten Primaria. 2002. 30:290–296.

15. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001. 285:2486–2497.

16. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002. 287:356–359.

17. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am. 1990. 17:509–516.

18. Nugent AP. The metabolic syndrome. BNF Nutr Bull. 2004. 29:36–43.

19. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990. 17:477–486.

20. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000. 163:1725–1729.

21. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trial. Diabetologia. 2004. 47:1914–1923.

22. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986. 61:1081–1090.

23. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia. 1989. 32:Suppl. 465A.

24. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate cancer Prostatic Dis. 1998. 1:157–162.

25. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003. 10:569–574.

26. Kim JH, Shim BS, Kim JS, Hong YS. Voiding dysfunction of men is associated metabolic syndrome. Korean J Urol. 2006. 47:257–262.